Impact of once-weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, randomised controlled STEP 5 trial

被引：0
|
作者：
Dimitriadis, Georgios K. [1 ]
Batterham, Rachel [2 ]
Bhatta, Meena [3 ]
Holst-Hansen, Thomas [3 ]
Kandler, Kristian [3 ]
Rigas, Georgia [4 ]
Garvey, W. Timothy [5 ]
机构：
[1] Kings Coll London, London, England
[2] UCL, Div Med, Obes Res Ctr, London, England
[3] Novo Nordisk AS, Soborg, Denmark
[4] St George Private Hosp, Dept Bariatr Metab Surg, Kogarah, NSW, Australia
[5] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL USA
来源：
OBESITY SURGERY | 2023年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [1] Impact of once-weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, randomised controlled STEP 5 trial
    Batterham, R. L.
    Bhatta, M.
    Holst-Hansen, T.
    Kandler, K.
    Rigas, G.
    Garvey, W. T.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S254 - S254
  • [2] The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
    Alabduljabbar, Khaled
    Al-Najim, Werd
    le Roux, Carel W.
    NUTRIENTS, 2022, 14 (11)
  • [3] Once-weekly semaglutide 2.4mg improved metabolic syndrome in adults with overweight or obesity: post hoc analysis of the STEP 1 trial
    Khan, Omar
    le Roux, Carel
    Davies, Melanie
    Frias, Juan
    Laursen, Peter Norkjaer
    Lingvay, Ildiko
    Machineni, Sriram
    Varbo, Anette
    Wilding, John
    Wallenstein, Signe
    Perreault, Leigh
    OBESITY SURGERY, 2022, 32 (SUPPL 1) : 32 - 32
  • [4] Associations between weight loss and glycaemic control with once-weekly semaglutide 1.0 mg and 2.4 mg in the STEP 2 trial
    Davies, M.
    Faerch, L.
    Goldman, B.
    Pakseresht, A.
    Pedersen, S.
    Rosenstock, J.
    Lingvay, I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S254 - S255
  • [5] Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
    Frias, Juan P.
    Deenadayalan, Srikanth
    Erichsen, Lars
    Knop, Filip K.
    Lingvay, Ildiko
    Macura, Stanislava
    Mathieu, Chantal
    Pedersen, Sue
    Davies, Melanie
    LANCET, 2023, 402 (10403): : 720 - 730
  • [6] Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg
    Kyrillos, Janine V.
    O'Neil, Patrick M.
    Wharton, Sean
    POSTGRADUATE MEDICINE, 2022, 134 : 1 - 4
  • [7] Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
    Perreault, Leigh
    Davies, Melanie
    Frias, Juan P.
    Laursen, Peter Norkjaer
    Lingvay, Ildiko
    Machineni, Sriram
    Varbo, Anette
    Wilding, John P. H.
    Wallenstein, Signe Olrik Rytter
    le Roux, Carel W.
    DIABETES CARE, 2022, 45 (10) : 2396 - 2405
  • [8] Once-weekly semaglutide 2.4 mg improved glucose metabolism and prediabetes in adults with overweight or obesity in the STEP 1 trial
    Perreault, L.
    Davies, M.
    Frias, J. P.
    Laursen, P. N.
    Lingvay, I.
    Machineni, S.
    Varbo, A.
    Wilding, J. P. H.
    Wallenstein, S. O. R.
    Le Roux, C. W.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 234 - 234
  • [9] Once-Weekly Semaglutide 2.4 mg Improved Glucose Metabolism and Prediabetes in Adults with Overweight/Obesity in the STEP 1 Trial
    Perreault, Leigh
    Davies, Melanie J.
    Frias, Juan P.
    Laursen, Peter N.
    Lingvay, Ildiko
    Machineni, Sriram
    Varbo, Anette
    Wilding, John
    Wallenstein, Signe O. R.
    Le Roux, Carel
    DIABETES, 2021, 70
  • [10] Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg
    Kelly, Aaron S.
    Arslanian, Silva
    Hesse, Dan
    Iversen, Aske Thorn
    Koerner, Antje
    Schmidt, Signe
    Sorrig, Rasmus
    Weghuber, Daniel
    Jastreboff, Ania M.
    OBESITY, 2023, 31 (08) : 2139 - 2149
12345